4D Lifetec AG
Liquid Biopsy Assay for early cancer detection
4D Lifetec AG is the pioneering company in non-genomic, immuno-oncologic blood assays for early cancer diagnostic. Due to its proprietary transformational DDS biomarker, 4D Lifetest™ has several possibilities to expand its market activities, become a key element in the diagnostic cascade for other major cancer types and support genomic liquid biopsy methods by adding high early detection sensitivity (> 90% at Stage I). 4D Lifetest™ Lung Dx is the company’s flagship product which is marketed with an initial focus on early lung cancer diagnostic. Additional applications (4D Lifetest™ Breast Dx, 4D Lifetest™ Prostate Dx, 4D Lifetest™ Colon Dx) are already CE IVD certified and ready to access the markets.
4D Lifetec participated in the Venture Leaders Biotech program in 2019.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
18.10.2023
4D Lifetec secures CHF 23.3 million to enhance cancer diagnosis (startupticker.ch)
22.02.2023
4D Lifetec establishes US presence with new branch office on MIT campus (venturelab.swiss)
21.02.2023
4D LifeTec establishes a presence in the US market (startupticker.ch)
13.01.2023
Seasoned executives to drive startups in the next phase (startupticker.ch)
No Jobs
Videos
Develop cancer detection to happen earlier
Documents
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
4D Lifetec AG
Liquid Biopsy Assay for early cancer detection
Website:
4dlifetec.com
Headquarter:
Cham
Foundation Date:
November 2014
Technology:
- Medtech
Sectors:
- Big Data
- Biotech
- Cancer
- Digital Health
- Diagnostics
- Screening
Support received
